News
RGLS
1.780
+1.14%
0.020
Weekly Report: what happened at RGLS last week (0715-0719)?
Weekly Report · 4d ago
Optimistic Outlook on Regulus’s RGLS8429 for ADPKD Despite Initial eGFR Concerns
TipRanks · 07/17 15:40
Regulus Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 07/16 12:21
HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $10 Price Target
Benzinga · 07/16 12:11
Buy Rating Affirmed for Regulus Therapeutics Amid Positive RGLS8429 Study Results
TipRanks · 07/16 10:23
Weekly Report: what happened at RGLS last week (0708-0712)?
Weekly Report · 07/15 10:11
Weekly Report: what happened at RGLS last week (0701-0705)?
Weekly Report · 07/08 10:12
Weekly Report: what happened at RGLS last week (0624-0628)?
Weekly Report · 07/01 10:12
Buy Rating Affirmed on Regulus Amid Promising ADPKD Trial Updates
TipRanks · 06/26 07:37
Regulus Therapeutics Price Target Raised to $28.00/Share From $11.00 by Canaccord Genuity
Dow Jones · 06/25 14:59
Regulus Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 06/25 14:59
Canaccord Genuity Maintains Buy on Regulus Therapeutics, Raises Price Target to $28
Benzinga · 06/25 14:49
Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
JP Morgan cut the price target for Sea Limited (NYSE:SE) from $84 to $78 on Monday. Morgan Stanley raised the price targets for Birkenstock Holding plc and Credo Technology Group Holding Ltd. UBS boosted the target for Cloudflare, Inc. And upgraded the stock of Ball Corporation.
Benzinga · 06/25 11:27
Regulus Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 06/25 10:57
Regulus Therapeutics Price Target Raised to $10.00/Share From $9.00 by HC Wainwright & Co.
Dow Jones · 06/25 10:57
HC Wainwright & Co. Maintains Buy on Regulus Therapeutics, Raises Price Target to $10
Benzinga · 06/25 10:48
REGULUS THERAPEUTICS INC <RGLS.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $10 FROM $9
Reuters · 06/25 10:27
Promising Phase 1b Results Elevate Regulus Therapeutics’ RGLS8429, Meriting a Buy Rating Upgrade
TipRanks · 06/25 10:25
Regulus’s Promising Early Results Tempered by Uncertainties: Hold Rating Maintained
TipRanks · 06/25 09:16
U.S. RESEARCH ROUNDUP-Alimera Sciences, Comtech Telecommunications, Eli Lilly
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Alimera Sciences, Comtech Telecommunications, Eli Lilly among companies with revised targets. Analysts raise their ratings on several companies, including Apple and FMC. Some analysts also raise their target prices on other companies.
Reuters · 06/25 07:19
More
Webull provides a variety of real-time RGLS stock news. You can receive the latest news about Regulus Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About RGLS
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.